Vorinostat
Hodgkins Lymphoma
OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
141 Active assets in the Hodgkins Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin St. Petersburg State Pavlov Medical University | Phase 2 | BBB |
Everolimus OHSU Knight Cancer Institute | Phase 2 | BBB |
Camustine VIVUS LLC | Phase 2 | BBB |
Methotrexate Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BBB |
Cyclosporin A City of Hope Medical Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Vorinostat is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BB
Indicative · Phase 2
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →